Department of Chemical and Biological Engineering, University of Wisconsin, 1415 Engineering Drive, Madison, Wisconsin 53706, USA.
Biochemistry. 2010 Sep 28;49(38):8276-89. doi: 10.1021/bi101280t.
β-Amyloid (Aβ) is the main protein component of the amyloid plaques associated with Alzheimer's disease. Transthyretin (TTR) is a homotetramer that circulates in both blood and cerebrospinal fluid. Wild-type (wt) TTR amyloid deposits are linked to senile systemic amyloidosis, a common disease of aging, while several TTR mutants are linked to familial amyloid polyneuropathy. Several recent studies provide support for the hypothesis that these two amyloidogenic proteins interact, and that this interaction is biologically relevant. For example, upregulation of TTR expression in Tg2576 mice was linked to protection from the toxic effects of Aβ deposition [Stein, T. D., and Johnson, J. A. (2002) J. Neurosci. 22, 7380-7388]. We examined the interaction of Aβ with wt TTR as well as two mutants: F87M/L110M, engineered to be a stable monomer, and T119M, a naturally occurring mutant with a tetrameric stability higher than that of the wild type. On the basis of enzyme-linked immunoassays as well as cross-linking experiments, we conclude that Aβ monomers bind more to TTR monomers than to TTR tetramers. The data further suggest that TTR tetramers interact preferably with Aβ aggregates rather than Aβ monomers. Through tandem mass spectrometry analysis of cross-linked TTR-Aβ fragments, we identified the A strand, in the inner β-sheet of TTR, as well as the EF helix, as regions of TTR that are involved with Aβ association. Light scattering and electron microscopy studies demonstrate that the outcome of the TTR-Aβ interaction strongly depends on TTR quaternary structure. While TTR tetramers may modestly enhance aggregation, TTR monomers decidedly arrest Aβ aggregate growth. These data provide important new insights into the nature of TTR-Aβ interactions. Such interactions may regulate TTR-mediated protection against Aβ toxicity.
β-淀粉样蛋白(Aβ)是与阿尔茨海默病相关的淀粉样斑块的主要蛋白成分。转甲状腺素蛋白(TTR)是一种四聚体,在血液和脑脊液中循环。野生型(wt)TTR 淀粉样沉积物与老年性全身性淀粉样变性有关,这是一种常见的老年疾病,而几种 TTR 突变体与家族性淀粉样多神经病有关。最近的几项研究支持了这样一种假设,即这两种淀粉样蛋白相互作用,并且这种相互作用具有生物学相关性。例如,Tg2576 小鼠中 TTR 表达的上调与 Aβ沉积的毒性作用的保护有关[Stein,T.D.和 Johnson,J.A.(2002)J. Neurosci. 22,7380-7388]。我们研究了 Aβ与 wt TTR 以及两种突变体的相互作用:F87M/L110M,设计为稳定的单体,以及 T119M,一种天然存在的突变体,其四聚体稳定性高于野生型。基于酶联免疫吸附测定以及交联实验,我们得出结论,Aβ单体与 TTR 单体的结合比与 TTR 四聚体的结合更紧密。数据进一步表明,TTR 四聚体更倾向于与 Aβ聚集体而不是 Aβ单体相互作用。通过对交联的 TTR-Aβ片段的串联质谱分析,我们确定了 TTR 中 A 链,即在 TTR 内部β-折叠中,以及 EF 螺旋,作为与 Aβ结合相关的 TTR 区域。光散射和电子显微镜研究表明,TTR-Aβ相互作用的结果强烈依赖于 TTR 的四级结构。虽然 TTR 四聚体可能适度增强聚集,但 TTR 单体肯定会阻止 Aβ聚集体的生长。这些数据为 TTR-Aβ相互作用的性质提供了重要的新见解。这种相互作用可能调节 TTR 介导的对 Aβ毒性的保护作用。